BNET Industries
Market Cap:$290.8M
Last Fiscal Year Sales:$8.0M
- Public
- US
Dow Jones Description
Since our inception in December 1995, SIGA has pursued the research, development and commercialization of novel products for the prevention and treatment of serious infectious diseases, including products for use in the defense against biological warfare agents such as smallpox and Arenaviruses. Our lead product, ST-246 ® , is an orally administered antiviral drug that targets orthopox viruses. In December 2005, the U.S. Food and Drug Administration (the "FDA") accepted our Investigational New Drug ("IND") application for ST-246 ® and granted the program "Fast-Track" status. In December 2006, the FDA granted Orphan Drug designation to ST-246 ® for the prevention and treatment of smallpox. In May 2009, we submitted a response to a Request for Proposal ("RFP") issued by the U.S. Biomedical Research and Development Agency ("BARDA") with respect to the purchase of 1.7 million courses of a smallpox antiviral (the " BARDA Smallpox RFP " ), and, in June 2009, BARDA informed us that our response to the BARDA Smallpox RFP was deemed technically acceptable and in the competitive range. There can be no assurance that SIGA or any other company will receive an award pursuant to this RFP. Further, any award on this RFP would be subject to negotiation of final contract terms and specifications; thus, the final terms under any contract with BARDA may be materially different than those indicated in this RFP. ...
Number of Employees 43
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
SIGA Technologies Reports Operating Results for the Third Quarter of 2009
-
$1.6 Million NIH Cooperative Agreement Supports SIGA Broad Spectrum Antiviral Research
News & Analysis
Filter by
siga technologies inc. - All News and Analysis
Small-Cap Biotechs: How to Separate The Contenders From The Pretenders
Smart Profits Report submits: By Marc Lichtenfeld I’m used to explosive gains in the biotech world, but I’ve never seen a moonshot quite like this… by Smart Profits Report
SIGA Technologies: Bioterror Stock Pick
Jeremy Hellman submits: To quote a story making the rounds Monday: The United States can expect a terrorist attack using nuclear or more likely biological weapons before 2013, reports a bipartisan commission in a study being briefed Tuesday to Vice President-elect Joe Biden. The report suggests...
SIGA Receives $8 Million in Financing Support from MacAndrews & Forbes
NEW YORK -- SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, today announced that one of its largest investors, MacAndrews & Forbes LLC, has agreed to supply as needed up to $8.0 million in financing. Under the agreement, SIGA...
Breaking Stock News.
M2 PRESSWIRE-17 January 2008-Financialbusinessnews.us: Breaking Stock NewsC1994-2008 M2 COMMUNICATIONS LTD RDATE:17012008 Boston, MA -- Republic Bancorp, Inc. (NASDAQ: RBCAA); SIGA Technologies, Inc. (NASDAQ: SIGA); Cognex Corporation (NASDAQ: CGNX); Oculus Innovative Sciences, Inc. (NASDAQ: OCLS); The Tootie Pie Company, Inc. (OTCBB:...
SIGA To Present at the 26th Annual JPMorgan Healthcare Conference
Dr. Eric Rose to be a Featured Panel Member of JPMorgan's Biodefense & Pandemic Flu Presentation NEW YORK -- SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens and protect the population at large, today announced that its Chief Executive...
SIGA CEO, Dr. Eric Rose, Selected to Serve as Member of National Biodefense Science Board
NEW YORK -- SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens and protect the population at large, today announced the appointment of the company's Chief Executive Officer, Dr. Eric Rose, to serve as an inaugural member of the newly formed...
SIGA Technologies Q2 2007 Earnings Call Transcript
Question-and-Answer SessionOperator [Operator Instructions] Your first question comes from the line of Joaquin inaudible from Nolan Berger Capital. Please proceed. Joaquin - Nolan Berger Capital Good morning guys. Eric A. Rose - Chief Executive Officer and Chairman of the Board Hi Joaquin, how are...
TheSUBWAY.coms Stock Market Standouts List for Tuesday, March 20, 2007:.
M2 PRESSWIRE-20 March 2007-Capital Research Group: TheSUBWAY.coms Stock Market Standouts List for Tuesday, March 20, 2007:C1994-2007 M2 COMMUNICATIONS LTD RDATE:20032007 TheSUBWAY.com: Announces the following stocks to its Stock Market Standouts List: Renhuang Pharmaceuticals, Inc. (OTCBB: RHGP), ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD),...
SIGA Technologies Announces Smallpox Drug Candidate Administered to Critically Ill Human Patient.
M2 PRESSWIRE-19 March 2007-Morning Movers: SIGA Technologies Announces Smallpox Drug Candidate Administered to Critically Ill Human PatientC1994-2007 M2 COMMUNICATIONS LTD RDATE:19032007 Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay a step ahead...
Bellwether Report.com is Tracking SIGA Technologies Inc.
M2 PRESSWIRE-24 October 2006-bellwetherreport.com: Bellwether Report.com is Tracking SIGA Technologies Inc.C1994-2006 M2 COMMUNICATIONS LTD RDATE:24102006 The Bellwether Report Takes Notice of SIGA Technologies Inc. (Nasdaq:SIGA) Say "ahhh" instead of "ow!" If development-stage SIGA Technologies has its way,...
- 1
- 2
Industry Transcripts by Seeking Alpha
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
-
Arena Pharmaceuticals Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ARNA
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- The 10 Weirdest Drug Stories of the Month 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes

